Former NFL LB Bryan Braman 'in the fight of his life' as he battles rare form of cancer
Bryan Braman, a former linebacker for the Houston Texans and Philadelphia Eagles, is currently battling a rare, aggressive form of cancer, his agent told KPRC 2 in Houston.
'At Stellato Sports, Bryan Braham has always stood for strength, resilience and leadership,' said Sean Stellato. 'He is a pillar and a staple of the underdog. Now, in the face of cancer, he embodies those qualities more than ever. If there is one person that I know that can beat cancer, it is Bryan Braman, who I have always considered family. He's in the fight of his life. Please support Bryan and keep him in your prayers.'
Advertisement
The 38-year-old Braman has undergone multiple surgeries and recently underwent a CAR T-cell reprogramming treatment program in Seattle, according to a GoFundMe set up to help the former NFLer.
"With the cancer that Bryan has, which is a VERY rare form of cancer, the Car-t treatment had the highest chance of success as the cells are reprogrammed to fight this cancer that is within Bryan. His cells did re-infuse themselves, and did in fact start reproducing within his bone marrow. At first the mass did start to shrink, but then the cancer started fighting back. At this point Bryan has had to start having chemo treatments that are designed for the treatment program Bryan is in.
"Bryan has had to undergo several surgical procedures. The main problem has been that Bryan has not been able to recover from the procedures because of his lowered immunity due to all of these treatments. By the time he was able to recover so he could continue with the chemo, the cancer has grown expedentially faster, and is is now growing around his vital organs.
"The Dr's are now concerned because of his treatment, his chemo options are very limited. They have tried all of the various treatment options, and unfortunately, none of them are working against this cancer. But Bryan has not given up. He is looking into other trial treatment programs, and is determined to never give up."
As of Saturday morning, nearly $55,000 has been raised for Braman, who was diagnosed in February.
Braman grew up in Spokane, Washington and was undrafted out of West Texas A&M. He ended up making the Texans' roster on special teams in 2011 and made his name known with a helmet-less tackle. One year later he was an alternate for the Pro Bowl.
Braman moved on to the Eagles in 2014 for three seasons. After an injury cut short his time with the New Orleans Saints in 2017, he returned to the Eagles that December and helped them win Super Bowl LII over the New England Patriots.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
IndyCar Honda 200 at Mid-Ohio qualifying, starting lineup, time
If you buy something through a link in this article, we may earn commission. Pricing and availability are subject to change. Championship points leader Alex Palou wins pole position for the IndyCar Series race in the Ohio countryside, his third pole start of the year. Christian Lundgaard will also start on the front row for the 90-lap race on Mid-Ohio's 13-turn, 2.26-mile road course. Scott Dixon has won 6 times at Mid-Ohio, most recently in 2019. Josef Newgarden has won twice and Pato O'Ward won in 2024. Advertisement Nathan Brown is your best IndyCar follow, and keep up with coverage throughout the season with IndyStar's motorsports newsletter. IndyCar starting grid for Honda Indy 200 at Mid-Ohio on July 6, 2025 Row 1 1, Alex Palou 2, Christian Lundgaard Row 2 3, Kyffin Simpson 4, Nolan Siegel Row 3 5, Colton Herta 6, Louis Foster Row 4 7, Kyle Kirkwood 8, Marcus Armstrong Row 5 9, Scott Dixon 10, Christian Rasmussen (will start 6 spots further back after making an unapproved engine change) Row 6 11, Marcus Ericsson 12, Alexander Rossi Row 7 13, Conor Daly 14, David Malukas Row 8 15, Pato O'Ward 16, Felix Rosenqvist Row 9 17, Santino Ferrucci Advertisement 18, Josef Newgarden Row 10 17, Sting Ray Robb 20, Graham Rahal Row 11 21, Scott McLaughlin 22, Will Power Row 12 23, Devlin DeFrancesco 24, Callum Ilott Row 13 25, Jacob Abel 26, Rinus Veekay Row 14 27, Robert Shwartzman Will Power is upset with Alex Palou after IndyCar practice at Mid-Ohio Who is leading IndyCar? 2025 IndyCar results Alex Palou has won six races and Kyle Kirkwood three. Palou's points lead is almost two full races of max points. Who won at Mid-Ohio in 2024? 2024 IndyCar results at Mid-Ohio Pato O'Ward edged Alex Palou at the finish line, swapping their starting positions. Scott McLaughlin completed the podium after starting 7th. Advertisement Alex Palou to Formula 1? Williams boss has 2 reasons for why not, and Palou agrees 'I missed it': Ex-Team Penske IndyCar leader relishing new chapter with Arrow McLaren Back to full strength: Team Penske names new leadership atop IndyCar, sports car teams IndyCar expert picks, predictions for Mid-Ohio From Nathan Brown, IndyStar We're in the back half of a 17-race season, and Palou and Kirkwood are the only drivers to take checkered flags. Is anyone besides Alex Palou or Kyle Kirkwood allowed to win a race? If so, who? Marcus Ericsson. Of all the drivers in the field sorely in need of a pick-me-up, the fact that Ericsson sits 21st in points just a single top-10 is one of the year's biggest headscratchers. And yet, he heads to a track where he's finished in the top 6 in 4 of his last 5 starts, and where he started and finished 5th a year ago. He's finished on the podium here before (2021, runner-up), and this is a track where Andretti Global has shown speed in years past. Advertisement What is something no one sees coming? Amazingly, we finally get our third winner of the year in Colton Herta. He has only done that in two of his last 10 pole starts. It will be his 10th career victory and Andretti Global's fourth of the year, its most since 2018. IndyCar Series schedule at Mid-Ohio in Lexington, Ohio (All times ET; all IndyCar sessions are on IndyCar Live, IndyCar Radio and Sirius XM Channel 218) IndyCar schedule at Mid-Ohio in Lexington, Ohio, on Sunday, July 6 9:30-10 a.m.: IndyCar warmup, FS1 10:30-11:30 a.m.: Indy NXT race, FS1 1 p.m.: IndyCar race, Fox What channel is IndyCar race at Mid-Ohio in Lexington, Ohio, on? TV: Coverage begins at 1 p.m. ET, Sunday, June 22, 2025, on Fox. Green flag is scheduled for 1:22 p.m. Will Buxton is the play-by-play voice, with analysts James Hinchcliffe and Townsend Bell. Kevin Lee and Jack Harvey are the pit reporters. Advertisement How can I stream the IndyCar race at Mid-Ohio in Lexington, Ohio, on Sunday, July 6? Fox Sports app. Watch free with a Fubo trial How can I listen to IndyCar race at Mid-Ohio in Lexington, Ohio, on Sunday, July 6? IndyCar Nation is on SiriusXM Channel 218, IndyCar Live and the IndyCar Radio Network (check affiliates for each race) Will it rain during the IndyCar race at Mid-Ohio in Lexington, Ohio? Sunday: Sunny skies and temperatures in the upper 80s. IndyCar at Mid-Ohio push-to-pass, tire allotment Push-to-pass: Drivers have 200 total seconds, in increments of up to 20 seconds. Advertisement Tire allotment: Five sets primary (hard/black sidewall) and five sets alternate for the weekend. Rookie drivers are allowed one additional set of primary tires. Teams must use one set of primary and one set of alternate tires unless wet conditions are declared. 2025 IndyCar Series schedule The 2025 IndyCar Series schedule includes 17 races, all televised on Fox. (Times are ET; %-downtown street course, &-road course, *-oval) March 2, St. Petersburg, Florida % (Winner: Alex Palou) March 23, Thermal, California & (Winner: Alex Palou) April 13, Long Beach, California % (Winner: Kyle Kirkwood) May 4, Birmingham, Alabama & (Winner: Alex Palou) Advertisement May 10, Indianapolis & (Winner: Alex Palou) May 25, Indianapolis 500 * (Winner: Alex Palou) June 1, Detroit % (Winner: Kyle Kirkwood) June 15, St. Louis * (Winner: Kyle Kirkwood) June 22, Elkhart Lake, Wisconsin & (Winner: Alex Palou) July 6, Lexington, Ohio &, 1 p.m. July 12, Newton, Iowa *, 5 p.m. July 13, Newton, Iowa *, 1 p.m. July 20, Toronto %, noon July 27, Monterey, California &, 3 p.m. Aug. 10, Portland &, 3 p.m. Aug. 24, Milwaukee *, 2 p.m. Aug. 31, Nashville *, 2:30 p.m. IndyCar drivers for 2025 (Team and drivers; *-Indianapolis 500 only) IndyCar Series 2025 points championship points (Through nine of 17 races) Advertisement Alex Palou, 386 points Kyle Kirkwood, 293 Pato O'Ward, 275 Felix Rosenqvist, 231 Scott Dixon, 231 Christian Lundgaard, 228 Will Power, 197 Scott McLaughlin, 190 Santino Ferrucci, 184 Colton Herta, 184 Marcus Armstrong, 183 David Malukas, 174 Alexander Rossi, 161 Rinus Veekay, 157 Christian Rasmussen, 150 Kyffin Simpson, 141 Josef Newgarden, 137 Conor Daly, 133 Graham Rahal, 133 Nolan Siegel, 128 Marcus Ericsson, 123 Robert Shwartzman, 104 Louis Foster, 102 Sting Ray Robb, 93 Devlin DeFrancesco, 89 Callum Ilott, 78 Jacob Abel, 56 Takuma Sato, 36 Helio Castroneves, 20 Ed Carpenter, 16 Jack Harvey, 12 Ryan Hunter-Reay, 10 Kyle Larson, 6 Marco Andretti, 5 This article originally appeared on Indianapolis Star: IndyCar Mid-Ohio qualifying results, starting lineup for Honda Indy 200
Yahoo
31 minutes ago
- Yahoo
ACHV: Achieve's Busy Day
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.
Yahoo
32 minutes ago
- Yahoo
Breaking down Will Power's exchange with Alex Palou during IndyCar at Mid-Ohio practice
Will Power's temper isn't quite what it once was, but he still isn't shy about airing complaints — even with the driver dominating the IndyCar Series in recent years. Power approached Alex Palou after Saturday morning's practice at Mid-Ohio, frustrated by what he felt was Palou's tepid pace, preventing him from turning full-speed laps in preparation for qualifying. Advertisement Fox Sports cameras caught their exchange on pit road, bleeping out some of Power's language. After Power walked away, Palou laughed and suggested Power complain to Barry Wanser, Palou's strategist, who was sitting on the timing stand. "He came out a lap later in front of me, staying there, and spent four laps going slow. Backing up, backing up, backing up, which is frustrating," Power told Fox Sports, adding that process repeated itself minutes later. Insider: Buckle up, IndyCar's silly season revolves around wily veteran Will Power. What we're hearing Power said Palou acknowledged the issue. Several drivers complained during practice and qualifying that others didn't allow them enough space to run full out on the 13-turn, 2.26-mile road course. Advertisement "Look, I think if you look at Practice 1 or 2, everybody is complaining about traffic, and we're all angry that we don't get clear laps. But maybe he thought we did something personal to him. For sure that was not the intention," Palou said in his post-qualifying news conference. "I don't know if you saw, but I was always like a second or two seconds in front of him. He was just having to back off. I never tried to defend or anything. "I think he was just a little bit upset, and that's OK. But yeah, I knew that he was coming (down pit road) — I just didn't want to start to get into an argument. Yeah, it happens. It was my first time with him, so it's good." Starting grid: IndyCar Honda 200 at Mid-Ohio qualifying "We're struggling," Power said. "We're trying to get an idea of what our car is doing, and if you keep backing up, losing tire temps, you don't know." Advertisement Palou qualified for pole position and Power 22nd. Get IndyStar's motor sports coverage sent directly to your inbox with our Motor Sports newsletter. This article originally appeared on Indianapolis Star: Will Power mad at Alex Palou after IndyCar practice at Mid-Ohio
